Shuichi Kaneko

机构：Kanazawa University, Kanazawa University Hospital · ORCID：0000-0002-3137-8183

发表论文 839 篇 · 总被引 32824 次 · h-index 93

代表论文

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 455)
• Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice (2024 · Molecular Therapy — Methods & Clinical Development · 被引 12)
• Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction–associated steatohepatitis (2024 · Hepatology Communications · 被引 12)
• Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study. (2024 · Journal of Clinical Oncology · 被引 11)
• LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma. (2025 · Journal of Clinical Oncology · 被引 7)
• A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 (2023 · Liver Cancer · 被引 7)